A generic operational strategy to qualify translational safety biomarkers.

The importance of using translational safety biomarkers that can predict, detect and monitor drug-induced toxicity during human trials is becoming increasingly recognized. However, suitable processes to qualify biomarkers in clinical studies have not yet been established. There is a need to define clear scientific guidelines to link biomarkers to clinical processes and clinical endpoints. To help define the operational approach for the qualification of safety biomarkers the IMI SAFE-T consortium has established a generic qualification strategy for new translational safety biomarkers that will allow early identification, assessment and management of drug-induced injuries throughout R&D.

[1]  C. Blandizzi,et al.  Healthy volunteers and early phases of clinical experimentation , 2010, European Journal of Clinical Pharmacology.

[2]  L. Lesko,et al.  Paving the Critical Path: How can Clinical Pharmacology Help Achieve the Vision? , 2007, Clinical pharmacology and therapeutics.

[3]  Binodh DeSilva,et al.  Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules , 2003, Pharmaceutical Research.

[4]  J. Wagner,et al.  Biomarkers and Surrogate End Points for Fit‐for‐Purpose Development and Regulatory Evaluation of New Drugs , 2007, Clinical pharmacology and therapeutics.

[5]  Jean W. Lee,et al.  Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[6]  J. Trojanowski,et al.  Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.

[7]  Xiao-Hua Zhou,et al.  Nonparametric Estimation of ROC Curves in the Absence of a Gold Standard , 2005, Biometrics.

[8]  Anika Ashok,et al.  ICH Harmonised Tripartite Guideline , 2009 .

[9]  Viswanath Devanarayan,et al.  Confirmatory reanalysis of incurred bioanalytical samples , 2007, The AAPS Journal.

[10]  M. Greiner,et al.  Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. , 2000, Preventive veterinary medicine.

[11]  Krishna Prasad,et al.  Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium , 2010, Nature Biotechnology.

[12]  Bruce W. Turnbull,et al.  Nonparametric estimation of ROC curves based on Bayesian models when the true disease state is unknown , 2007 .

[13]  Lucila Ohno-Machado,et al.  The use of receiver operating characteristic curves in biomedical informatics , 2005, J. Biomed. Informatics.

[14]  E. K. Harris.  Effects of intra- and interindividual variation on the appropriate use of normal ranges. , 1974, Clinical chemistry.

[15]  F. Goodsaid,et al.  Translational Medicine and the Value of Biomarker Qualification , 2010, Science Translational Medicine.

[16]  Wesley O. Johnson,et al.  Bayesian inferences for receiver operating characteristic curves in the absence of a gold standard , 2006 .

[17]  Jean W. Lee,et al.  Specificity and selectivity evaluations of ligand binding assay of protein therapeutics against concomitant drugs and related endogenous proteins , 2007, The AAPS Journal.

[18]  M. Enserink.  Helsinki's New Clinical Rules: Fewer Placebos, More Disclosure , 2000, Science.

[19]  Viswanath Devanarayan,et al.  Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement , 2006, Pharmaceutical Research.